2013-01-29 11:42:45 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to China National Medicines Corporation Ltd and produced a Rating Update Report, rating the company's attractiveness to long-term investors.
Ilhavo, Portugal – SADIF Investment Analytics, announces a new Rating Update Report covering China National Medicines Corporation Ltd (600511). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential China National Medicines Corporation Ltd investor.
Report Summary: China National Medicines Corporation Ltd is an above average quality company with a positive outlook. China National Medicines Corporation Ltd has medium business growth and is run by efficient management. The trend in China National Medicines Corporation Ltd fair value exchange rate against its closest rated-competitor, Chongqing Tong Jun Ge Co.,Ltd, has been appreciating over the past 2 weeks. When compared to its closest competitor, China National Medicines Corporation Ltd shows similar overvaluation and is equally
likely to outperform the market.
The 3-page report breaks down the Total StockMark into its three components – business, management and price, performing an in-depth analysis of China National Medicines Corporation Ltd for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, West Services, Advisen, Alacra-Datadownlink, Factiva, INTERNET SECURITIES and LEXIS/NEXIS or directly from SADIF-Investment Analytics at:
About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering sixteen different markets and over 12,000 companies. The StockMarks™ system is based on proven investment principles and is designed to drive long-term shareholder returns.